Outcomes for liver cancer patients are highly stage dependent. Interventions designed to be curative, such as minimally invasive ablation, tumour resection, or transplantation, are limited to those diagnosed at an early stage. According to the SEER database, five-year survival rates for localised liver cancer are approximately 37%, declining sharply to 13% and 3% for regional and distant disease, respectively. These disparities underscore the importance of early detection, as delayed diagnosis remains a key barrier to better outcomes. Current liver screening tools rely on ultrasound, alpha-fetoprotein (AFP) testing, and imaging (CT/MRI). However, these approaches suffer from limited sensitivity in early-stage disease, resulting in many patients being diagnosed at an advanced stage.
Recent advances in diagnostic technologies are focused on addressing this gap. Helio Genomics has developed a blood-based, multi-analyte approach that detects tumor-associated epigenetic signals in the circulating cell-free DNA (cfDNA), alongside protein biomarkers. This non-invasive strategy enables earlier identification of cancer-associated signals, including cases where conventional imaging may be inconclusive, and it has the potential to improve detection in high-risk populations.
Go deeper with GlobalData
Recently, Helio Genomics announced a collaboration with Quest Diagnostics to make its HelioLiver test broadly available across Quest’s extensive US provider network. This partnership enables physicians to order the test through existing clinical infrastructure. By embedding the test within standard laboratory pathways, this approach may help reduce delays in diagnosis.
From a clinical perspective, earlier detection may increase the proportion of patients diagnosed at a resectable stage. While there are currently no approved perioperative treatments for liver cancer, multiple late-stage trials are evaluating immunotherapy-based strategies in this setting. These include the Phase III IMbrave050 for the combination of Roche’s Tecentriq (atezolizumab) with bevacizumab in the adjuvant setting and the Phase III CARES-009 study Hengrui’s camrelizumab plus rivoceranib in the perioperative setting. This is particularly relevant given the high rates of recurrence observed even following curative-intent resection, highlighting the need for improved perioperative management strategies.
Taken together, improved diagnostic capabilities and advances in perioperative systemic therapy may act synergistically to reshape the liver cancer treatment paradigm. Earlier detection has the potential to shift the stage at diagnosis and expand the population eligible for curative intervention, while emerging immunotherapy-based regimens may reduce recurrence risk in these patients. As a result, integration of advanced diagnostics into routine clinical practice may not only improve early detection but also amplify the clinical impact of downstream therapeutic strategies, ultimately improving long-term outcomes in liver cancer.
